

IN THE CLAIMS

This listing of claims will replace all prior versions and listings of the claims in the application.

1-58. (Cancelled)

59. (Currently Amended) A pharmaceutical composition comprising an agent for suppressing an immune response and a gastrin/CCK receptor ligand in the absence of a EGF receptor ligand, wherein the agent is a rapamycin and the gastrin/CCK receptor ligand is gastrin ~~17Leu15~~ 17(Leu15).

60.-65. (Cancelled)

66. (Original) The composition according to claim 59, further comprising Tacrolimus.

67-77. (Cancelled)

78. (Currently amended) A method of treating a diabetic subject comprising administering to said subject an agent that increases islet neogenesis and an agent that suppresses an immune response in the absence of a EGF receptor ligand, wherein said agent that increases islet neogenesis is gastrin~~17Leu15~~ 17(Leu15) and said agent that suppresses an immune response is a rapamycin.

79.-83. (Cancelled)

84. (Previously presented) The method according to claim 78 further comprising administering Tacrolimus.

85. (Cancelled)

86. (Previously Presented) The method according to claim 78, wherein said agent that increases islet neogenesis and said agent that suppresses an immune response are administered sequentially.

87. (Previously Presented) The method according to claim 78, wherein the subject is a human.

88. (Cancelled)

89. (Previously Presented) The method according to claim 78, wherein the diabetic subject has recent onset diabetes.

90. (Cancelled)

91. (New) A pharmaceutical composition comprising rapamycin and a composition for islet neogenesis therapy, wherein said composition for islet neogenesis therapy consists of gastrin17(Leu15).

92. (New) A method of treating a diabetic subject comprising administering to said subject a pharmaceutical composition comprising rapamycin and an agent that increases islet neogenesis, wherein said agent that increases islet neogenesis consists of gastrin17(Leu15).